Physician profile
Caleb Heath
NPI 1013388404
$12,470.40
in general payments reported to CMS, 2019-2025
53 companies · $3,433 in 2025
The $3,433 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,471 · 2022: $1,739 · 2023: $2,281 · 2024: $3,545 · 2025: $3,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,022 · Travel and Lodging: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,022.23 |
| Travel and Lodging | $237.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,860.74 | 2021-2025 | |
| Ucb, INC. | $1,364.54 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $1,234.20 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Livanova USA, INC. | $761.31 | 2024 | Vns Therapy |
| Biohaven Pharmaceuticals, INC. | $637.92 | 2021 | |
| Neurelis, INC. | $496.98 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $481.66 | 2022-2025 | |
| Lundbeck LLC | $428.23 | 2021-2025 | Vyepti |
| Sk Life Science, INC. | $401.78 | 2022-2025 | |
| Pfizer INC. | $357.29 | 2022-2025 | |
| Axsome Therapeutics, INC. | $265.90 | 2025 | Symbravo |
| Tanabe Pharma America, INC. | $251.08 | 2024-2025 | Radicava |
| Sunovion Pharmaceuticals INC. | $220.75 | 2021-2022 | |
| Lilly USA, LLC | $217.73 | 2022-2023 | Emgality, Reyvow, Amyvid |
| Biohaven Pharmaceutical Holding Company LTD. | $215.20 | 2022 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $207.70 | 2021-2025 | Nuplazid, Daybue |
| Alnylam Pharmaceuticals INC. | $160.11 | 2022-2025 | Amvuttra |
| Neurocrine Biosciences, INC. | $154.71 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $134.60 | 2024-2025 | Hyqvia |
| Sumitomo Pharma America, INC. | $123.04 | 2023-2024 | Aptiom |
| Ipsen Biopharmaceuticals, INC | $114.47 | 2023-2025 | Dysport |
| Eisai INC. | $98.10 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $92.52 | 2022-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $82.78 | 2024-2025 | Wainua, Andexxa |
| Argenx US, INC. | $80.96 | 2024-2025 | Vyvgart Hytrulo |
| Catalyst Pharmaceuticals, INC. | $75.50 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $62.10 | 2021-2022 | |
| Immedica Pharma US, INC. | $62.02 | 2024 | |
| Aucta Pharmaceuticals, INC. | $61.76 | 2025 | Motpoly Xr |
| Emd Serono, INC. | $58.96 | 2022-2025 | Mavenclad |
| Biogen, INC. | $54.96 | 2024-2025 | Skyclarys |
| Csl Behring | $52.37 | 2023 | Hizentra |
| Genentech USA, INC. | $52.31 | 2023-2025 | Evrysdi, Ocrevus Zunovo |
| Grifols USA, LLC | $50.21 | 2025 | Gamunex-C |
| Kedrion Biopharma, INC. | $46.34 | 2024-2025 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Merz Pharmaceuticals, LLC | $45.62 | 2023-2025 | Xeomin |
| Allergan, INC. | $42.85 | 2021 | |
| Amneal Pharmaceuticals LLC | $42.81 | 2022-2023 | Rytary |
| Novartis Pharmaceuticals Corporation | $41.58 | 2025 | |
| Acorda Therapeutics, INC | $30.82 | 2022 | |
| Averitas Pharma INC. | $27.14 | 2024 | Qutenza |
| Janssen Biotech, INC. | $26.06 | 2025 | |
| Banner Life Sciences, LLC | $24.32 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.68 | 2024 | Keveyis |
| Scilex Pharmaceuticals INC. | $19.86 | 2025 | |
| Avanir Pharmaceuticals, INC. | $18.99 | 2021 | |
| Resmed Corp | $18.94 | 2021 | |
| Insightec,INC | $17.48 | 2025 | Exablate |
| Inspire Medical Systems, INC. | $16.42 | 2025 | Inspire |
| Avion Pharmaceuticals | $14.59 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.49 | 2021 | |
| Mdd US Operations, LLC | $13.47 | 2025 | |
| Janssen Pharmaceuticals, INC | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Heath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.